Form 8-K - Current report:
SEC Accession No. 0001193125-25-009577
Filing Date
2025-01-21
Accepted
2025-01-21 16:31:34
Documents
16
Period of Report
2025-01-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d927067d8k.htm   iXBRL 8-K 28322
2 EX-5.1 d927067dex51.htm EX-5.1 4983
3 EX-10.1 d927067dex101.htm EX-10.1 240410
4 EX-99.1 d927067dex991.htm EX-99.1 11183
  Complete submission text file 0001193125-25-009577.txt   483901

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA vinc-20250121.xsd EX-101.SCH 2838
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE vinc-20250121_lab.xml EX-101.LAB 17978
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vinc-20250121_pre.xml EX-101.PRE 11250
18 EXTRACTED XBRL INSTANCE DOCUMENT d927067d8k_htm.xml XML 3631
Mailing Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306
Business Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306 650-800-6676
Vincerx Pharma, Inc. (Filer) CIK: 0001796129 (see all company filings)

EIN.: 833197402 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39244 | Film No.: 25542891
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)